15/05/2026
FUNDS TO DELIVER GAME-CHANGING APPROACH TO CANCER SCREENING AND TREATMENT
Health researchers at Royal North Shore Hospital and the Kolling Institute will lead a major advancement in cancer care following a $3.75 million Translational Program Grant from the Cancer Institute NSW.
The funding will support the testing and implementation of liquid biopsy technology into routine cancer diagnosis and treatment. Liquid biopsies use a simple blood test to detect and monitor cancer by identifying tumour DNA in the bloodstream, offering a less invasive alternative to traditional surgical biopsies.
Clinician researcher Professor Anthony Gill said the technique has the potential to transform cancer care by helping detect cancer earlier, monitor treatment response, and identify whether disease has returned.
“This technology can pick up small amounts of DNA shed by cancer in the blood, providing crucial information to guide treatment,” he said.
The approach is also expected to significantly improve access to care for rural and remote patients, who often travel long distances for invasive testing.
“Patients from rural and isolated communities often travel hundreds of kilometres for biopsies. With this technique, a simple blood test can be taken closer to home,” Professor Gill said.
RNSH oncologist Professor Nick Pavlakis said liquid biopsies represent a combination of tests used at different stages of cancer care, from screening to monitoring recurrence and treatment response.
The initiative is expected to play a key role in shaping the future of precision cancer medicine across NSW.